Factor Bioscience News Today

Adicet Bio (NASDAQ:ACET – Get Free Report) and Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability. Insider and Institutional Ownership 83.9% of Adicet […]

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the

Lineage Cell Therapeutics, Inc. ; class=js-l-obf link link--blue

/PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies,...

NEW YORK, NY / ACCESSWIRE / December 20, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued

/PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its...

SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on...

Exacis CEO Gregory Fiore, MD, commented, “We welcome CCRM as a key partner to allow us to rapidly advance our virus-free manufacturing...

Author Bio Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles. What happened Shares of Brooklyn ImmunoTherapeutics (NYSEMKT:BTX), no stranger to sharp stock price movements lately, zoomed more than 6% higher o...

Share this article Share this article CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, revealed key data related to its engineered iPSC-derived NK-cell platform at the American Society of Gene & Cell Therapy 24th Annual Meeting. These data include the successful generation of functional NK cells from iPSCs engineered to contain a bialle...